HBI-002 to treat parkinson?s disease

Ended Project Grant Awarded Last action

Award ID
R41NS122576
Recipient
Awarding agency
Obligated
$1,720,982

Award facts

Completion date
Originally
Funding
  • $1,267,824.00 Federal
  • $453,158.00 Non-federal
Place of performance
California, USA

Award details come from USAspending.gov.

Description

Abstract
The goal of the proposed project is to evaluate the potential of HBI-002, a novel oral formulation of carbon monoxide (CO), as a neuroprotective agent in parkinson's disease (PD). A growing body of research suggests that low doses of CO - and the heme oxygenase (HO) enzymes that generate endogenous CO - protect against neuronal cell loss in PD, and epidemiologic studies have associated cigarette smoking with a lower risk of PD. Together, these observations suggest that low doses of CO may be neuroprotective in PD. Nicotine does not appear to underlie the protective effect of tobacco, as a clinical study of nicotine in PD did not show significant improvement. At low levels (

Transactions

Action Federal Non-federal Date
Amendment $0 $0
Amendment $180,754 $0
Amendment $180,754 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $453,158 $0
Original award $453,158 $453,158

Quick answers

Who received award R41NS122576?

R41NS122576 was awarded to Hillhurst Biopharmaceuticals, Inc. by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on September 20, 2021.

How much is award R41NS122576 worth?

$1,720,982 has been obligated on R41NS122576: $1,267,824 in federal funding and $453,158 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award